Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

IVVD

Invivyd Inc

Sep 20 • 04:00PM ET

1.20

Dollar change -0.02
Percentage change -1.64	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI IWM IWN VXF SCHA VTWO IWC RSSL VTWV SCHB

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.80	Insider Own	39.18%	Shs Outstand	110.16M	Perf Week	4.35%
Market Cap	143.33M	Forward P/E	-	EPS next Y	-0.10	Insider Trans	-0.24%	Shs Float	72.65M	Perf Month	36.67%
Income	-203.84M	PEG	-	EPS next Q	-0.33	Inst Own	60.07%	Short Float	10.51%	Perf Quarter	-3.23%
Sales	2.26M	P/S	63.42	EPS this Y	61.33%	Inst Trans	1.52%	Short Ratio	12.15	Perf Half Y	-61.17%
Book/sh	1.18	P/B	1.02	EPS next Y	86.43%	ROA	-82.73%	Short Interest	7.64M	Perf Year	-31.43%
Cash/sh	1.24	P/C	0.97	EPS next 5Y	-	ROE	-96.56%	52W Range	0.81 - 5.20	Perf YTD	-69.54%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-144.93%	52W High	-76.90%	Beta	0.63
Dividend TTM	-	Quick Ratio	4.57	Sales past 5Y	0.00%	Gross Margin	5.04%	52W Low	47.86%	ATR (14)	0.11
Dividend Ex-Date	-	Current Ratio	4.71	EPS Y/Y TTM	-12.04%	Oper. Margin	-9326.33%	RSI (14)	60.11	Volatility	7.60% 12.51%
Employees	94	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-9003.40%	Recom	1.50	Target Price	8.65
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	13.75%	Payout	-	Rel Volume	1.98	Prev Close	1.22
Sales Surprise	-54.72%	EPS Surprise	-7.15%	Sales Q/Q	-	Earnings	Aug 14 BMO	Avg Volume	628.20K	Price	1.20
SMA20	20.84%	SMA50	11.46%	SMA200	-52.31%	Trades		Volume	1,244,499	Change	-1.64%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-05-24	Upgrade	Guggenheim	Neutral → Buy	$9
Mar-26-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$4 → $10
Dec-19-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$1 → $4
May-01-23	Initiated	H.C. Wainwright	Buy	$5

Sep-12-24 07:01AM	Invivyd at the Ready for Upcoming Respiratory Virus Season with PEMGARDA (pemivibart) to Help Protect Vulnerable Immunocompromised Persons from COVID-19 (GlobeNewswire) +12.75%
Sep-05-24 07:01AM	Invivyd to Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-04-24 07:01AM	Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA (GlobeNewswire)
Sep-03-24 07:01AM	Invivyd Announces Continued Neutralizing Activity of PEMGARDA (pemivibart) Against Dominant SARS-CoV-2 Variants KP.3.1.1 and LB.1, and Other Variants of Interest (GlobeNewswire)
Aug-27-24 07:01AM	Invivyd Announces PEMGARDA (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial (GlobeNewswire) -28.67%
02:43AM	Loading…
Aug-15-24 02:43AM	Q2 2024 Invivyd Inc Earnings Call (Thomson Reuters StreetEvents) +6.12%
Aug-14-24 09:10AM	Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -7.55%
08:01AM	Invivyd Reports Second Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Aug-12-24 04:01PM	Invivyd to Host Conference Call Discussing Second Quarter 2024 Financial Results and Business Highlights (GlobeNewswire) -6.31% +9.84%
Jul-01-24 07:01AM	Invivyd Announces its Addition to the Russell 2000 and Russell 3000 Indexes (GlobeNewswire) +9.09%
Jun-14-24 07:01AM	Invivyd Announces Antiviral Activity of VYD222 (pemivibart) Against SARS-CoV-2 KP.1.1 FLiRT & KP.3 Variants (GlobeNewswire) -7.06%
Jun-03-24 04:01PM	Invivyd to Participate at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-31-24 07:05AM	Invivyd Announces General Alignment with U.S. FDA on a Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial Monoclonal Antibodies (GlobeNewswire)
07:00AM	Invivyd Announces the Appointment of Timothy Lee as Chief Commercial Officer (GlobeNewswire)
May-29-24 07:00AM	Invivyd to Present Data at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and 2024 American Transplant Congress (ATC) (GlobeNewswire)
07:00AM	Loading…
May-22-24 07:00AM	Invivyd Elects Two New Independent Members to its Board of Directors (GlobeNewswire)
May-13-24 04:01PM	Invivyd to Participate at the H.C. Wainwright 2nd Annual BioConnect Investor Conference (GlobeNewswire)
10:44AM	Invivyd, Inc. (NASDAQ:IVVD) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-10-24 03:25PM	Invivyd Inc (IVVD) Reports Q1 2024 Financial Results: A Detailed Analysis (GuruFocus.com) -6.61%
May-09-24 10:56PM	IVVD Stock Earnings: Invivyd Meets EPS for Q1 2024 (InvestorPlace)
04:01PM	Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
May-07-24 07:30AM	Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback (GlobeNewswire) +6.36%
May-02-24 05:13PM	Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
Apr-30-24 07:30AM	Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash Position (GlobeNewswire) +6.73%
Apr-15-24 07:30AM	Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA (GlobeNewswire)
Apr-12-24 07:30AM	Invivyd Announces CEO Transition (GlobeNewswire)
Apr-04-24 04:01PM	Invivyd Provides PEMGARDA Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million (GlobeNewswire) -8.91% -7.82%
Mar-28-24 01:53PM	IVVD Stock Earnings: Invivyd Misses EPS for Q4 2023 (InvestorPlace) +11.00%
07:00AM	Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Mar-22-24 03:28PM	Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial (GlobeNewswire) +41.10%
03:04PM	Loading…
03:04PM	Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19 (GlobeNewswire)
Feb-05-24 04:02PM	Invivyd to Participate at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-29-24 12:35PM	3 Groundbreaking Biotech Stocks to Invest in Now (InvestorPlace) +11.31%
Jan-12-24 12:00PM	All You Need to Know About Invivyd, Inc. (IVVD) Rating Upgrade to Strong Buy (Zacks)
Jan-03-24 07:00AM	Invivyd Submits Request for Emergency Use Authorization (EUA) to U.S. FDA for VYD222 for the Pre-exposure Prevention of COVID-19 in Immunocompromised Adults and Adolescents (GlobeNewswire)
Dec-23-23 05:29AM	Invivyd Stock More Than Doubled Last Week. Is It Too Late to Buy? (Motley Fool)
Dec-19-23 11:52AM	Invivyd (IVVD) Surges on Positive Data From COVID-19 Study (Zacks) -7.52%
Dec-18-23 07:00AM	Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19 (GlobeNewswire) +120.25%
Nov-13-23 10:21AM	Invivyd, Inc. (NASDAQ:IVVD) Q3 2023 Earnings Call Transcript (Insider Monkey) +7.14%
Nov-10-23 08:35AM	Q3 2023 Invivyd Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-09-23 04:01PM	Invivyd Reports Third Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire) -7.89%
Nov-02-23 04:01PM	Invivyd to Host Conference Call Discussing Third Quarter 2023 Financial Results and Business Highlights (GlobeNewswire) +5.44%
Oct-31-23 04:01PM	Invivyd to Participate in Upcoming Investor Conferences (GlobeNewswire) -6.96%
Sep-11-23 07:00AM	Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19 (GlobeNewswire)
Sep-06-23 08:17PM	7 Biotech Stocks to Sell in September Before They Crash & Burn (InvestorPlace)
07:00AM	Invivyd to Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-05-23 07:00AM	Invivyd Appoints William Duke as Chief Financial Officer (GlobeNewswire)
Aug-29-23 01:13PM	Invivyd (IVVD) Stock Rises 18% in 3 Months: Here's Why (Zacks)
Aug-15-23 05:45AM	Invivyd, Inc. (NASDAQ:IVVD) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-11-23 06:43AM	Q2 2023 Invivyd Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-10-23 04:01PM	Invivyd Reports Second Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Aug-03-23 04:01PM	Invivyd to Host Conference Call Discussing Second Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Jul-27-23 04:01PM	Invivyd Announces Appointment of Sara Cotter to Board Of Directors (GlobeNewswire)
Jul-17-23 02:15PM	Invivyd's COVID-19 Antibody Shows Favorable Safety, Tolerability Profile For Immunocompromised People (Benzinga)
07:00AM	Invivyd Announces Additional Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People (GlobeNewswire)
Jun-26-23 07:00AM	Invivyd Announces General Alignment with FDA on Pathway to Potential EUA for VYD222 and Anticipated Follow-On Monoclonal Antibody Candidates Designed to Prevent COVID-19 (GlobeNewswire)
Jun-22-23 01:07PM	Invivyd Says Investigational Antibody Shows Potential To Prevent Symptomatic COVID-19 (Benzinga) -6.19%
07:00AM	Invivyd Announces Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People (GlobeNewswire)
Jun-01-23 07:00AM	Invivyd to Participate at the Jefferies Healthcare Conference (GlobeNewswire) -16.67%
May-23-23 06:25AM	Is Invivyd (NASDAQ:IVVD) In A Good Position To Deliver On Growth Plans? (Simply Wall St.) +19.72%
May-11-23 04:01PM	Invivyd Reports First Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
May-04-23 04:01PM	Invivyd to Host Conference Call Discussing First Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Apr-25-23 04:01PM	Invivyd to Participate at H.C. Wainwrights BioConnect Investor Conference (GlobeNewswire)
07:00AM	Invivyd Announces the FDA Has Cleared Its IND Application for VYD222, a Monoclonal Antibody Candidate for Prevention of COVID-19, and Provides Phase 1 VYD222 Clinical Trial Update (GlobeNewswire)
Apr-14-23 09:35AM	After Plunging -26.71% in 4 Weeks, Here's Why the Trend Might Reverse for Invivyd, Inc. (IVVD) (Zacks)
Apr-12-23 07:00AM	Invivyd Appoints Robert Allen as Chief Scientific Officer and Stacy Price as Chief Technology and Manufacturing Officer (GlobeNewswire)
Mar-30-23 04:01PM	Invivyd Doses First Participants in Phase 1 Trial of VYD222, a Novel Monoclonal Antibody Candidate for COVID-19 (GlobeNewswire) -8.14%
Mar-28-23 04:58AM	Invivyd, Inc. (NASDAQ:IVVD) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-24-23 06:41AM	Full Year 2022 Invivyd Inc Earnings Call (Thomson Reuters StreetEvents) -8.39%
Mar-23-23 04:01PM	Invivyd Reports Full Year 2022 Financial Results and Business Highlights (GlobeNewswire)
Mar-22-23 04:30PM	Invivyd Publishes Model for Evaluating Biomarker Correlates of Protection for Monoclonal Antibodies Against Symptomatic COVID-19 (GlobeNewswire) -9.55%
Mar-16-23 07:00AM	Invivyd to Host Conference Call Discussing Full Year 2022 Financial Results and Business Highlights (GlobeNewswire)
Mar-06-23 07:00AM	Invivyd Optimizes Development Efficiency with Election of VYD222 for Near-Term Clinical Advancement to Address Urgent Unmet Need for COVID-19 Monoclonal Antibodies (GlobeNewswire)
Feb-28-23 07:00AM	Invivyd to Participate at Cowens 43rd Annual Healthcare Conference (GlobeNewswire)
Feb-03-23 07:30AM	Invivyd Announces Changes to Executive Team (GlobeNewswire) -7.89%
Jan-27-23 05:59PM	Why Shares of Invivyd Jumped This Week (Motley Fool) -8.47%
Jan-02-23 12:00PM	Invivyd, Inc. (IVVD) Upgraded to Buy: Here's Why (Zacks)
Dec-19-22 07:00AM	Invivyd Presented Joint Industry Rationale on Potential Expedited Development Pathways for Monoclonal Antibodies at FDA-EMA Workshop (GlobeNewswire)
Dec-13-22 02:37PM	We Think Invivyd (NASDAQ:IVVD) Needs To Drive Business Growth Carefully (Simply Wall St.)
Dec-06-22 04:01PM	Invivyd Appoints Jeremy Gowler as Chief Operating and Commercial Officer, Promotes Pete Schmidt, M.D., to Chief Medical Officer (GlobeNewswire) -8.45% +5.90%
Nov-22-22 09:20PM	The Petri Dish: J&J vet joins Moderna as U.S. GM; Invivyd partners with investment firm (American City Business Journals)
Nov-17-22 01:58PM	Alphabet Inc (GOOGL) Investment Portfolio: Top 15 Companies (Insider Monkey)
07:00AM	Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical Development in Infectious Diseases Including COVID-19 (GlobeNewswire)
Nov-10-22 04:01PM	Invivyd Reports Third Quarter 2022 Financial Results and Business Highlights (GlobeNewswire) +7.55%
Nov-09-22 07:00AM	Invivyd to Participate in Fireside Chat at the Jefferies London Healthcare Conference (GlobeNewswire) -9.07%
Nov-02-22 07:00AM	Invivyd to Host Conference Call on November 10 to Discuss Third Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire) -9.88%
Oct-24-22 04:01PM	Invivyd Announces the Appointment of Christine Lindenboom to Board of Directors (GlobeNewswire)
Oct-17-22 02:37PM	Adagio Therapeutics, now Invivyd, retools its strategy after losing two executives (American City Business Journals)
Oct-13-22 04:26PM	Invivyd Names Fred Driscoll as Interim CFO, Cuts Some Positions (The Wall Street Journal) +5.44% -6.02%
04:01PM	Invivyd Appoints Fred Driscoll as Interim Chief Financial Officer and Announces Resource Reallocation to Maximize Integrated Discovery Platform (GlobeNewswire)
Oct-12-22 04:01PM	Invivyd to Present Multiple Posters Highlighting Clinical Data from Adintrevimab During ID Week 2022 (GlobeNewswire)
Oct-03-22 08:05AM	In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews David Hering CEO, Invivyd Inc. (ACCESSWIRE)

Invivyd, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers, ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren Russo and Laura Walker on June 3, 2020 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MCGUIRE TERRANCE	Director	May 29 '24	Sale	1.66	112,381	186,575	4,688,079	May 31 05:09 PM
Adimab, LLC	10% Owner	Jan 19 '24	Sale	3.95	5,000,000	19,750,000	21,687,906	Jan 22 04:18 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IVVD

Invivyd Inc

Upgrade your FINVIZ experience